| 释义 |
- Insomnia GABAA receptor potentiators Orexin receptor antagonists Melatonin receptor agonists Others/undefined
- Hypersomnia/narcolepsy Monoaminergics GHB receptor agonists H3 receptor inverse agonists GABAA receptor inhibitors Others/undefined
- See also
- References
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. {{TOC limit|3}}InsomniaGABAA receptor potentiators- EVT-201 – GABAA receptor positive allosteric modulator
- Lorediplon (GF-015535-00) – GABAA receptor positive allosteric modulator
- Remimazolam (HR-7056) – GABAA receptor positive allosteric modulator
- Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator
Orexin receptor antagonists- Filorexant (MK-6096) – orexin receptor antagonist
- Lemborexant (E-2006, LEM-10, LEM-5) – orexin receptor antagonist
- Nemorexant (ACT-541468) – orexin receptor antagonist
- Seltorexant (MIN-202, JNJ,42847922, JNJ-922) – selective OX2 receptor antagonist
Melatonin receptor agonists- Piromelatine (Neu-P11) – melatonin receptor agonist and 5-HT1A and 5-HT1D receptor agonist
Others/undefined- Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / complex mechanism of action
- Lumateperone (ITI-007, ITI-722) – atypical antipsychotic / complex mechanism of action
- S-117957 (V-117957) – undefined mechanism of action
Hypersomnia/narcolepsyMonoaminergics- Flecainide/modafinil (THN-102) – modafinil (dopamine reuptake inhibitor) and flecainide (antiarrhythmic) combination
- JZP-507 – dopamine receptor agonist
- Mazindol controlled release (NLS-1001, NLS-1) – norepinephrine-predominant serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
- Phacetoperane (NLS-3) – norepinephrine–dopamine reuptake inhibitor (NDRI)
- Solriamfetol (JZP-110, ADX-N05) – weak NDRI
GHB receptor agonists- FT-218 (sodium oxybate controlled release) – GHB and GABAB receptor agonist
- JZP-258 (oxybate mixed salt solution) – GHB and GABAB receptor agonist
- JZP-386 (C-10323; deuterated sodium oxybate) – GHB and GABAB receptor agonist
- JZP-507 (oxybate mixed salt solution) – GHB and GABAB receptor agonist
H3 receptor inverse agonists- LGD-3437 – H3 receptor antagonist
- Pitolisant (Wakix; BF2.649) – H3 receptor inverse agonist
GABAA receptor inhibitors- GR-3027 – GABAA receptor negative allosteric modulator
- Pentylenetetrazole (BTD-001) – GABAA receptor negative allosteric modulator
Others/undefined- TS-091 (TS-0911) – undefined mechanism of action
See also- List of investigational drugs
References{{Insomnia pharmacotherapies}}{{Hypnotics}}{{Stimulants}} 5 : Experimental drugs|Hypnotics|Drug-related lists|Sedatives|Stimulants |